601607 上海医药
已收盘 10-23 15:00:00
资讯
新帖
简况
股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》
证券之星 · 02:50
股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》
上海医药终止I025-A研发项目
财中社 · 10-23 17:50
上海医药终止I025-A研发项目
上海医药（601607）10月20日主力资金净卖出213.26万元
证券之星 · 10-21
上海医药（601607）10月20日主力资金净卖出213.26万元
【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等
证券之星 · 10-12
【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等
股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》
证券之星 · 10-12
股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》
上海医药(601607.SH)：氯维地平乳状注射液获得批准生产
智通财经 · 10-09
上海医药(601607.SH)：氯维地平乳状注射液获得批准生产
股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第五次会议决议公告》
证券之星 · 10-08
股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第五次会议决议公告》
9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元
每日经济新闻 · 09-30
9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元
上海医药：拟不低于1.99亿美元出售Zeus Investment Limited及其附属公司股权
格隆汇 · 09-29
上海医药：拟不低于1.99亿美元出售Zeus Investment Limited及其附属公司股权
上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%
证券之星 · 09-28
上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
央广财经 · 09-28
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产
证券之星 · 09-28
上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产
上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产
智通财经 · 09-28
上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产
上海医药：下属公司紫杉醇注射液获药品注册证书
财中社 · 09-28
上海医药：下属公司紫杉醇注射液获药品注册证书
每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价
证券之星 · 09-13
每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价
上海医药：每股派0.10元，股权登记日为9月17日
南方财经网 · 09-11
上海医药：每股派0.10元，股权登记日为9月17日
股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》
证券之星 · 09-11
股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》
上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价
智通财经 · 09-10
上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价
股市必读：上海医药（601607）9月9日董秘有最新回复
证券之星 · 09-10
股市必读：上海医药（601607）9月9日董秘有最新回复
上海医药：若涉及大股东减持事宜会及时履行信息披露义务
证券之星 · 09-09
上海医药：若涉及大股东减持事宜会及时履行信息披露义务
暂无数据
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是药品、医疗器械、大健康产品、医药商业。公司再度入选《财富》世界500强和《PharmExec》2026全球制药企业50强榜单，排名为第411位和第39位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.17,"timestamp":1792738800000,"preClose":16.2,"halted":0,"volume":12776544,"delay":0,"changeRate":-0.0019,"floatShares":2789000000,"shares":3708000000,"eps":1.2864,"marketStatus":"已收盘","change":-0.03,"latestTime":"10-23 15:00:00","open":16.2,"high":16.32,"low":16,"amount":207000000,"amplitude":0.0198,"askPrice":16.18,"askSize":136,"bidPrice":16.17,"bidSize":137,"shortable":0,"etf":0,"ttmEps":1.2864,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":16.2,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":17.82,"lowLimit":14.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.77,"roa":"--","peRate":12.569963,"roe":"4.51%","epsLYR":1.54,"committee":0.479895,"marketValue":59964000000,"turnoverRate":0.0046,"status":1,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.02,"timestamp":1792742889003,"preClose":10.88,"halted":0,"volume":1146100,"delay":0,"premium":"-42.04"},"floatMarketCap":45101000000},"requestUrl":"/m/hq/s/601607/tweets","defaultTab":"tweets","newsList":[{"id":"2678136120","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136120?lang=zh_cn&edition=full","pubTime":"2026-10-26 02:50","pubTimestamp":1792954220,"startTime":"0","endTime":"0","summary":"公司公告汇总上海医药集团股份有限公司关于药品临床试验进展的公告上海医药决定终止I025-A研发项目的临床试验及后续开发。上海医药集团股份有限公司关于召开2026年第三季度业绩说明会的公告上海医药将于2026年11月2日10:00–11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司经营成果及财务状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","601607","BK0012","BK0099","BK0020","BK0028","02607","BK0188","BK0184","BK0187","BK1197","BK0209","BK0175","BK0097","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677923879","title":"上海医药终止I025-A研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2677923879","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677923879?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:50","pubTimestamp":1792749000,"startTime":"0","endTime":"0","summary":"10月23日，上海医药（601607/02607）发布公告，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I025-A研发项目。I025-A是靶向HER2的酪氨酸激酶抑制剂（TKI），拟用于晚期实体瘤的治疗。2021年7月，该项目获国家药品监督管理局批准开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906392052.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906392052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK0028","BK0099","BK0209","BK0184","BK0175","BK0187","BK1197","BK0012","601607","BK0183","BK0097","BK0188","BK0020","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677648543","title":"上海医药（601607）10月20日主力资金净卖出213.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677648543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677648543?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:35","pubTimestamp":1792542916,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月20日收盘，上海医药报收于16.45元，下跌1.56%，换手率0.37%，成交量10.22万手，成交额1.69亿元。10月20日的资金流向数据方面，主力资金净流出213.26万元，占总成交额1.27%，游资资金净流入1193.56万元，占总成交额7.08%，散户资金净流出980.3万元，占总成交额5.82%。融券方面，融券卖出4800.0股，融券偿还4100.0股，融券余量23.48万股，融券余额386.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0099","BK0187","601607","BK0175","BK0012","BK0028","BK0209","BK0188","02607","BK1197","BK0196","BK0020","BK0097","BK0184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872321","title":"【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674872321?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:26","pubTimestamp":1791804371,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于10月9日公布的信息整理，成都市前沿类脑人工智能创新中心有限公司天使轮融资，融资额2.5亿人民币，参与投资的机构包括上海医药，四川省中试平台有限公司，成都科创投集团。前沿类脑中心是一家脑机接口研发应用服务商，自主研发非侵入式脑机接口软硬件，包括双通道脑电+单通道心电多模态干电极采集模组，可实时捕捉脑电与生理信号。数据来源：天眼查APP以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200029706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0028","BK0188","BK0187","BK0196","CNHmain","601607","UCmain","02607","MCNHmain","BK0012","BK0097","CYB","BK0184","BK1197","BK0209","BK0175","MUCmain","BK0099","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674843048","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674843048","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674843048?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:43","pubTimestamp":1791740589,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月9日主力资金净流出1524.51万元，占总成交额5.3%； 公司公告汇总：氯维地平乳状注射液获国家药监局批准生产，公司已投入研发费用约5,220万元。公司公告汇总上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告上海医药集团股份有限公司下属上海上药第一生化药业有限公司收到国家药监局颁发的氯维地平乳状注射液《药品注册证书》，该药品符合药品注册有关要求，批准生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0097","BK0099","BK0175","BK0028","BK0196","BK1197","BK0188","02607","BK0187","BK0183","BK0020","BK0184","601607","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831293","title":"上海医药(601607.SH)：氯维地平乳状注射液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831293","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674831293?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:42","pubTimestamp":1791531746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药第一生化药业有限公司收到国家药品监督管理局颁发的关于氯维地平乳状注射液的《药品注册证书》，该药品获得批准生产。该药品主要用于治疗不适宜口服或预期口服药物治疗效果不佳的高血压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0028","02607","BK0188","BK0012","BK0184","BK0187","BK0099","BK1197","BK0097","BK0209","BK0196","601607","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673801495","title":"股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第五次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673801495","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673801495?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:07","pubTimestamp":1791392830,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，上海医药报收于16.22元，上涨1.38%，换手率0.41%，成交量11.42万手，成交额1.85亿元。公司公告汇总：上海医药董事会审议通过转让Zeus Investment Limited及其附属公司股权事项，标的公司企业价值为396,732,460美元。公司公告汇总上海医药集团股份有限公司第九届董事会第五次会议决议公告上海医药于2026年9月28日召开第九届董事会第五次会议，审议通过《关于转让Zeus Investment Limited及其附属公司股权的议案》和《关于高级管理人员年度经营业绩考核与薪酬方案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0196","BK0012","BK0097","BK0188","BK0020","BK0099","BK0184","BK0209","BK0028","BK0183","BK0175","BK0187","601607","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671622323","title":"9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671622323","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671622323?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:51","pubTimestamp":1790725887,"startTime":"0","endTime":"0","summary":"9月29日晚间，上海医药（SH601607，股价16元，市值593亿元）公告称，公司拟与春华资本共同出售ZeusInvestmentLimited（以下简称ZIL或标的公司）及其附属公司全部股权，标的公司企业价值确定为3.97亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609303887043645.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609303887043645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671094214","title":"上海医药：拟不低于1.99亿美元出售Zeus Investment Limited及其附属公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2671094214","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671094214?lang=zh_cn&edition=full","pubTime":"2026-09-29 20:49","pubTimestamp":1790686195,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0020","BK0175","601607","BK0209","BK0188","BK0099","BK0183","BK0184","BK0196","BK0097","BK0012","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253228","title":"上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670253228?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:14","pubTimestamp":1790604868,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，上海医药报收于15.89元，较前一交易日下跌0.81%，最新总市值为589.26亿元。该股当日开盘16.01元，最高16.11元，最低15.83元，成交额达1.41亿元，换手率为0.32%。近日，上海医药集团股份有限公司发布关于紫杉醇注射液获得批准生产的公告。公告显示，公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的《药品注册证书》，紫杉醇注射液获得批准生产。截至公告日，公司已投入研发费用约451万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","02607","BK0188","BK0175","BK0196","BK0183","BK0020","BK0012","BK0097","601607","BK0028","BK0187","BK1197","BK0099","BK0184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670875258","title":"沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花","url":"https://stock-news.laohu8.com/highlight/detail?id=2670875258","media":"央广财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670875258?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:22","pubTimestamp":1790601766,"startTime":"0","endTime":"0","summary":"央广网北京9月28日消息（记者牛谷月）9月28日晚间，沪市（含科创板）超20家上市公司集中发布多项利好公告，内容涵盖股份回购增持、资产重组、药品获批、重大经营合同落地等。多家企业以真金白银彰显对自身长期发展的信心，同时披露业务拓展新进展，向市场传递积极信号。回购增持成为本次晚间公告的重头戏，共有12家公司发布相关方案或实施进展。其中，两家公司抛出全新回购预案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885425388.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885425388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456846285.SGD","688032","600690","LU2148510915.USD","600720","BK0012","BK0028","688111","603707","BK0183","BK0277","BK0044","BK0175","BK0187","603296","BK0015","LU2097828805.USD","LU0456827905.SGD","LU1720050803.USD","IE0005HP3H50.USD","BK0231","BK0201","603195","BK0235","BK0020","LU2097828474.EUR","BK0196","LU1969619763.USD","BK0209","603310","BK0067","LU1580142542.USD","LU2097828714.EUR","601607","LU1794554557.SGD","BK0026","BK0097","BK0184","688349","SGXZ49509284.SGD","BK0259","605303","601117","BK0010","SGXZ81163826.USD","BK0000","601126","688251","LU2580892862.HKD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670233026","title":"上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670233026","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670233026?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:42","pubTimestamp":1790588538,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属常州制药厂收到国家药监局颁发的艾司奥美拉唑镁肠溶胶囊《药品注册证书》，该药品获得批准生产。该药品适用于胃食管反流病、根除幽门螺杆菌等，公司已投入研发费用约519万元。2025年中国大陆医院采购该药品金额为6.39亿元。此次获批有利于扩大市场份额，但存在销售不达预期风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800022872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0175","BK1197","BK0099","BK0020","02607","BK0209","601607","BK0028","BK0012","BK0097","BK0188","BK0184","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670877212","title":"上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670877212","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670877212?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:27","pubTimestamp":1790584048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药东英(江苏)药业有限公司(以下简称“上药东英”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于注射用硫酸艾沙康唑(以下简称“该药品”)的《药品注册证书》(证书编号：2026S03379)，该药品获得批准生产。注射用硫酸艾沙康唑适用于治疗成人和1岁及以上儿童患者下列感染：侵袭性曲霉病、侵袭性毛霉病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0097","BK0099","BK0175","BK0028","BK0196","BK1197","BK0188","02607","BK0187","BK0183","BK0020","BK0184","601607","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670723287","title":"上海医药：下属公司紫杉醇注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2670723287","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670723287?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:17","pubTimestamp":1790583420,"startTime":"0","endTime":"0","summary":"9月28日，上海医药（601607/02607）发布公告，近日，公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的关于紫杉醇注射液的《药品注册证书》，该药品获得批准生产。紫杉醇注射液适用于进展期卵巢癌的一线、后继治疗及淋巴结阳性的乳腺癌患者在含阿霉素标准方案联合化疗后的辅助治疗等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885220435.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885220435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0209","BK0188","BK0012","BK0175","BK0097","BK0196","BK0187","BK0028","BK0099","BK1197","BK0020","BK0183","BK0184","601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507911","title":"每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507911?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:13","pubTimestamp":1789236790,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，上海医药报收于16.29元，较上周的16.62元下跌1.99%。公司公告汇总上海医药集团股份有限公司发布2026年半年度权益分派实施公告，本次利润分配经2025年年度股东会审议通过。上海医药集团股份有限公司下属上海禾丰制药有限公司收到国家药品监督管理局颁发的《药品补充申请批准通知书》，盐酸林可霉素注射液通过仿制药质量和疗效一致性评价。2025年7月，上药禾丰提交一致性评价申请并获受理，截至公告日研发投入约197万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0188","BK0184","BK0097","BK0196","BK0209","601607","BK0183","BK0028","BK1197","BK0012","02607","BK0099","BK0175","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666823540","title":"上海医药：每股派0.10元，股权登记日为9月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2666823540","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666823540?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:52","pubTimestamp":1789116720,"startTime":"0","endTime":"0","summary":"南财智讯9月11日电，上海医药发布2026年半年度权益分派实施公告，每股派0.10元（含税），股权登记日为9月17日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113872118437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113872118437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","601607","BK0175","BK0187","BK0209","02607","BK0196","BK0188","BK0183","BK0012","BK0184","BK0097","BK0099","BK1197","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666974865","title":"股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666974865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666974865?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:10","pubTimestamp":1789060222,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上海禾丰制药有限公司盐酸林可霉素注射液通过仿制药一致性评价，2025年该药品中国大陆医院采购金额为2168万元，截至公告日研发投入约197万元。公司公告汇总上海医药集团股份有限公司2026年半年度权益分派实施公告本次利润分配经2026年6月25日召开的2025年年度股东会审议通过，每股派发现金红利0.10元（含税），以公司总股本3,708,361,809股为基数，共计派发现金红利370,836,180.90元，其中A股现金红利278,928,910.50元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0028","02607","BK0188","BK0012","BK0184","BK0187","BK0099","BK1197","BK0097","BK0209","BK0196","601607","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567287","title":"上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567287","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666567287?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:53","pubTimestamp":1789037606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海禾丰制药有限公司收到国家药品监督管理局颁发的关于盐酸林可霉素注射液的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。该药品适用于由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染，但仅适用于对青霉素过敏的患者或经医生判断不宜使用青霉素的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0028","BK0099","BK0209","BK0184","BK0175","BK0187","BK1197","BK0012","601607","BK0183","BK0097","BK0188","BK0020","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532844","title":"股市必读：上海医药（601607）9月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666532844?lang=zh_cn&edition=full","pubTime":"2026-09-10 01:32","pubTimestamp":1788975135,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘，上海医药报收于16.48元，下跌0.54%，换手率0.2%，成交量5.63万手，成交额9282.21万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000002038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","601607","BK0012","BK0099","BK0020","BK0028","02607","BK0188","BK0184","BK0187","BK1197","BK0209","BK0175","BK0097","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581029","title":"上海医药：若涉及大股东减持事宜会及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581029?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:57","pubTimestamp":1788947825,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药(601607)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，云南白药的36个月的减持期已经结束，该公司是否考虑减持公司股票？上海医药回复：尊敬的投资者您好，若涉及大股东减持事宜，公司会按照监管规则的要求及时履行相应的信息披露义务。目前题述一事暂未涉及，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900030720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","02607","BK0020","BK0097","BK0175","BK0012","BK0183","BK0187","BK0196","BK0184","601607","BK0188","BK0028","BK0099","BK1197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792965109108,"stockEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":0.0068},{"period":"3month","weight":-0.0067},{"period":"6month","weight":-0.0159},{"period":"1year","weight":-0.09},{"period":"ytd","weight":-0.0635}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是药品、医疗器械、大健康产品、医药商业。公司再度入选《财富》世界500强和《PharmExec》2026全球制药企业50强榜单，排名为第411位和第39位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}